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Aims Elevated serum uric acid concentration (SUA) has been associated with an increased risk of cardiovascular disease,
but this may be due to unmeasured confounders. We examined the association between SUA and outcomes as well
as the effect of sacubitril/valsartan on SUA in patients with heart failure with reduced ejection fraction (HFrEF) in
PARADIGM-HF.
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Methods
and results
The association between SUA and the primary composite outcome of cardiovascular death or heart failure (HF)
hospitalization, its components, and all-cause mortality was examined using Cox regression analyses among 8213
patients using quintiles (Q1–Q5) of SUA adjusted for baseline prognostic variables including estimated glomerular
filtration rate (eGFR), diuretic dose, and log N-terminal pro-brain natriuretic peptide. Change in SUA from baseline
over 12months was also evaluated in each treatment group. Patients in Q5 (SUA ≥8.6mg/dL) compared with Q1
(<5.4mg/dL) were younger (62.8 vs. 64.2 years), more often male (88.7% vs. 63.1%), had lower systolic blood pressure
(119 vs. 123mmHg), lower eGFR (57.4 vs. 76.6mL/min/1.73m2), and greater diuretic use. Higher SUAwas associated
with a higher risk of the primary outcome (adjusted hazard ratios) Q5 vs. Q1= 1.28 [95% confidence intervals
(1.09–1.50), P= 0.003], cardiovascular death [1.44 (1.11–1.77), P= 0.001], HF hospitalization [1.37 (1.11–1.70),
P= 0.004], and all-cause mortality [1.36 (1.13–1.64), P= 0.001]. Compared with enalapril, sacubitril/valsartan
reduced SUA by 0.24 (0.17–0.32) mg/dL over 12months (P< 0.0001). Sacubitril/valsartan improved outcomes,
irrespective of SUA concentration.
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Conclusion Serum uric acid concentration was an independent predictor of worse outcomes after multivariable adjustment in
patients with HFrEF. Compared with enalapril, sacubitril/valsartan reduced SUA and improved outcomes irrespective
of SUA.
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Introduction
Uric acid (UA) is the final product of purine metabolism and the
serum concentration of UA (SUA) reflects the balance between
dietary intake of purines, the synthesis of UA by xanthine oxidase
(along with superoxide) and UA excretion, principally by the
kidneys but also through the gastrointestinal tract.1,2 Diuretic
treatment is also associated with high SUA, probably because
diuretics impair UA excretion.
As well as potentially reflecting oxidative stress as a consequence
of xanthine oxidase activity,1 UA may itself have harmful effects
such as increasing expression of cytokines and chemokines, induc-
ing inflammation, impairing endothelial function and activating the
renin–angiotensin system.2
Hyperuricemia is common in many forms of cardiovascu-
lar disease, including heart failure (HF).3 In patients with acute
and chronic HF, higher SUA is associated with worse clinical
outcomes.4,5 Whether SUA is an independent predictor of out-
come is less certain as renal function and use of diuretics (and
diuretic dose) has been variably adjusted for. Additionally, only one
prior study has adjusted for natriuretic peptide levels and that was
a study in acute HF.6
The effect of treatments for HF on UA concentration is also
of interest and UA lowering agents have been investigated as a
potential therapy for HF.7,8 We have, therefore, examined the
predictive value of SUA in the Prospective comparison of ARNI
with ACEI to Determine Impact on Global Mortality and morbidity
in Heart Failure trial (PARADIGM-HF)9 and determined the effect
of sacubitril/valsartan (formerly known as LCZ696) on SUA.
Methods
Patients and procedures
The design and primary results of PARADIGM-HF have been
reported previously.9–11 Briefly, PARADIGM-HF was a random-
ized, double-blinded comparison of the ARNI sacubitril/valsartan
with enalapril in patients with chronic HF with reduced ejection
fraction (HFrEF). Eligibility criteria at screening included New York
Heart Association (NYHA) classes II–IV, left ventricular ejection
fraction (LVEF)≤ 40% (changed to ≤35% by amendment), and ele-
vated natriuretic peptides. Exclusion criteria at screening included
symptomatic hypotension or systolic blood pressure< 100mmHg,
estimated glomerular filtration rate (eGFR) <30mL/min/1.73m2, and
potassium >5.2mmol/L.
On trial entry, ongoing therapy with angiotensin-converting enzyme
(ACE) inhibitor or angiotensin receptor blocker (ARB) was stopped
and patients entered sequential run-in, first receiving enalapril 10mg
b.i.d. for 2weeks followed by sacubitril/valsartan for additional
4–6weeks up titrated from 100mg to 200mg b.i.d. Patients toler-
ating both drugs at these target doses were randomly assigned to
double-blinded therapy with sacubitril/valsartan or enalapril in a 1:1
ratio.
Measurement of SUA was performed at screening, during run-in
(when changing from enalapril to sacubitril/valsartan), at randomiza-
tion, and after 2, 4, and 12months of follow-up and yearly thereafter.
Evaluations of SUA were performed through a central laboratory.
SUA was converted from 𝜇mol/L to mg/dL by division with 59.48. ..
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.. The upper limit of normal for the SUA assay used was 8.0mg/dL for
men and 7.3mg/dL for women aged 66–90 years, and 6.9mg/dL for
women aged 18–65 years.
Outcomes
The primary endpoint in PARADIGM-HF was a composite of cardio-
vascular death and HF hospitalization. In this study, we investigated the
association between SUA and the risk of the primary outcome, each
of its components, and all-cause mortality. All endpoints were adjudi-
cated by a clinical endpoint committee in a blinded fashion. We also
compared the effects of the randomized treatment on SUA 4, 12, and
24months after randomization, as described below.
Statistical analyses
Baseline characteristics are presented as frequencies and percentages
for categorical variables and means with standard deviation or medi-
ans with interquartile range for continuous variables. Differences in
baseline characteristics were tested using 𝜒2 test for categorical vari-
ables and analysis of variance (ANOVA) or Kruskal–Wallis test for
continuous variables. Use of loop diuretics at baseline was grouped
in categories of furosemide equivalents: 40mg furosemide= 20mg
torasemide= 1mg bumetanide. Non-loop diuretics (primarily thiazide
and indapamide) were categorized as ‘other’.
Incidence rates for each outcome of interest are presented per
100 person years of follow-up. Event rates in each SUA quintile
were estimated by the Kaplan–Meier method and compared using
the log-rank test. Cox proportional hazards regression models were
used to compare hazard ratios (HRs) with 95% confidence intervals
(CIs) according to SUA quintiles. In multivariable models, the HR
was adjusted for the following baseline characteristics: age, sex, race,
region, systolic blood pressure, heart rate, ejection fraction, NYHA
class, history of HF hospitalization, duration of HF, atrial fibrillation,
diabetes, body mass index, prior myocardial infarction, prior stroke,
eGFR, haemoglobin, sodium, albumin, randomized treatment (sacu-
bitril/valsartan), diuretic dose, and log transformed N-terminal pro
brain natriuretic peptide (NT-proBNP).
The association between SUA and each outcome was also assessed
in an adjusted model using a restricted cubic spline with five knots using
SUA of 7.0mg/dL as reference.3
For the risk of each of the outcomes, there were no interactions
between SUA levels and sex. The proportional hazards assumption
was evaluated using plots of Schoenfeld residuals vs. log time and found
valid, as was the assumption of linearity of continuous variables.
Changes in SUA were assessed by repeated measures mixed model
with the baseline score as a covariate, and treatment, region, time,
and treatment by time interaction as fixed effects, with a common
unstructured covariance for each treatment group.
Analyses were performed using Stata version 13 (Stata Corp.,
College Station, TX, USA) and SAS version 9.4 (SAS Institute Inc.,
Cary, NC, USA). All P-values are two-sided, and a P-value <0.05 was
considered significant.
Results
Of the 8399 patients randomized, 8213 had a SUA measurement
at randomization. Mean SUA was 6.9± 2.0mg/dL, 7.1± 2.0mg/dL
in men and 6.1±1.8mg/dL in women (P< 0.001) (distributions of
SUA overall and according to sex and region are illustrated in the
supplementary material online, Figures S1 and S2).
© 2017 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Baseline characteristics
Serum uric acid concentration at randomization
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Q1
(n= 1635)
Q2
(n= 1696)
Q3
(n= 1688)
Q4
(n= 1643)
Q5
(n=1551)
P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Serum uric acid (mg/dL), mean± SD 4.4± 0.7 5.8± 0.3 6.7± 0.3 7.9± 0.4 9.2± 1.2
mg/dL, range 0.3–5.3 5.4–6.2 6.3–7.2 7.3–8.5 8.6–17.1
Age at screening (years) 64.16±11.19 64.00±10.98 64.21±11.25 63.61±11.65 62.83±11.84 0.003
Female sex 603 (36.9%) 427 (25.2%) 338 (20.0%) 250 (15.2%) 176 (11.3%) <0.001
Randomized to sacubitril/valsartan 802 (49.1%) 849 (50.1%) 825 (48.9%) 831 (50.6%) 785 (50.6%) 0.77
Region <0.001
North America 92 (5.6%) 98 (5.8%) 128 (7.6%) 129 (7.9%) 141 (9.1%)
Latin America 342 (20.9%) 302 (17.8%) 276 (16.4%) 280 (17.0%) 211 (13.6%)
Western Europe 282 (17.2%) 360 (21.2%) 432 (25.6%) 427 (26.0%) 484 (31.2%)
Central Europe 640 (39.1%) 617 (36.4%) 579 (34.3%) 496 (30.2%) 419 (27.0%)
Asia/Pacific and other 279 (17.1%) 319 (18.8%) 273 (16.2%) 311 (18.9%) 296 (19.1%)
Race <0.001
White 1080 (66.1%) 1102 (65.0%) 1148 (68.0%) 1064 (64.8%) 999 (64.4%)
Black 70 (4.3%) 76 (4.5%) 82 (4.9%) 92 (5.6%) 102 (6.6%)
Asia 272 (16.6%) 324 (19.1%) 280 (16.6%) 317 (19.3%) 308 (19.9%)
Other 213 (13.0%) 194 (11.4%) 178 (10.5%) 170 (10.3%) 142 (9.2%)
Systolic blood pressure (mmHg) 123.38±15.04 123.03±15.79 121.10±15.43 120.40± 14.73 118.55±14.94 <0.001
Heart rate (b.p.m.) 72.13±11.28 72.05±11.79 71.81±12.07 72.56±12.22 73.45±12.79 0.001
eGFR 60mL/min/1.73m2 76.61± 21.67 71.82±19.08 67.81±18.10 64.22±18.17 57.38±18.05 <0.001
Serum creatinine (𝜇mol/L) 84.95± 21.88 92.27± 22.34 98.06± 22.96 104.79± 24.22 117.83± 28.20 <0.001
Ischaemic HF aetiology 1007 (61.6%) 1001 (59.0%) 1021 (60.5%) 983 (59.8%) 900 (58.0%) 0.291
Ejection fraction (%) 29.98± 6.03 29.93± 6.06 29.57± 6.17 29.22± 6.33 28.63± 6.37 <0.001
Body mass index (kg/m2) 27.31± 5.16 27.61± 5.44 28.14± 5.34 28.67± 5.73 29.15± 5.79 <0.001
Current smoking 225 (13.8%) 264 (15.6%) 234 (13.9%) 226 (13.8%) 232 (15.0%) 0.440
NYHA class 0.001
I 66 (4.0%) 82 (4.8%) 76 (4.5%) 82 (5.0%) 77 (5.0%)
II 1164 (71.2%) 1209 (71.3%) 1210 (71.7%) 1191 (72.5%) 1016 (65.5%)
III 391 (23.9%) 390 (23.0%) 388 (23.0%) 363 (22.1%) 436 (28.1%)
IV 13 (0.8%) 14 (0.8%) 10 (0.6%) 6 (0.4%) 16 (1.0%)
Unknown 1 (0.1%) 1 (0.1%) 4 (0.2%) 1 (0.1%) 6 (0.4%)
Duration of HF <0.001
≤1 year 553 (33.8%) 537 (31.7%) 503 (29.8%) 468 (28.5%) 417 (26.9%)
1–5 years 597 (36.5%) 682 (40.2%) 644 (38.2%) 644 (39.2%) 605 (39.0%)
>5 years 485 (29.7%) 477 (28.1%) 541 (32.0%) 531 (32.3%) 529 (34.1%)
A history of
Hypertension 1152 (70.5%) 1216 (71.7%) 1191 (70.6%) 1158 (70.5%) 1084 (69.9%) 0.847
Diabetes 555 (33.9%) 570 (33.6%) 577 (34.2%) 562 (34.2%) 579 (37.3%) 0.171
Myocardial infarction 704 (43.1%) 689 (40.6%) 761 (45.1%) 718 (43.7%) 666 (42.9%) 0.126
Valvular heart disease 98 (6.0%) 116 (6.8%) 128 (7.6%) 114 (6.9%) 136 (8.8%) 0.038
Atrial fibrillation 507 (31.0%) 551 (32.5%) 608 (36.0%) 661 (40.2%) 688 (44.4%) <0.001
HF hospitalization 958 (58.6%) 1009 (59.5%) 1055 (62.5%) 1060 (64.5%) 1080 (69.6%) <0.001
Stroke 138 (8.4%) 132 (7.8%) 138 (8.2%) 148 (9.0%) 152 (9.8%) 0.282
COPD 182 (11.1%) 202 (11.9%) 213 (12.6%) 239 (14.5%) 218 (14.1%) 0.018
Cancer 83 (5.1%) 81 (4.8%) 80 (4.7%) 85 (5.2%) 72 (4.6%) 0.946
Medications
Beta-blocker 1516 (92.7%) 1578 (93.0%) 1571 (93.1%) 1537 (93.5%) 1439 (92.8%) 0.898
Mineralocorticoid receptor antagonist 849 (51.9%) 889 (52.4%) 947 (56.1%) 967 (58.9%) 926 (59.7%) <0.001
Digoxin 409 (25.0%) 493 (29.1%) 496 (29.4%) 549 (33.4%) 543 (35.0%) <0.001
Diuretics <0.001
None 465 (28.4%) 407 (24.0%) 347 (20.6%) 262 (15.9%) 159 (10.3%)
Loop diuretic – furosemide <40mg 450 (27.5%) 492 (29.0%) 495 (29.3%) 459 (27.9%) 355 (22.9%)
Loop diuretic – furosemide 40–80mg 449 (27.5%) 482 (28.4%) 528 (31.3%) 537 (32.7%) 551 (35.5%)
Loop diuretic – furosemide >80mg 174 (10.6%) 215 (12.7%) 231 (13.7%) 296 (18.0%) 437 (28.2%)
Other 97 (5.9%) 100 (5.9%) 87 (5.2%) 89 (5.4%) 49 (3.2%)
© 2017 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Continued
Serum uric acid concentration at randomization
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Q1
(n= 1635)
Q2
(n= 1696)
Q3
(n= 1688)
Q4
(n= 1643)
Q5
(n=1551)
P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Uric acid lowering drugs 0.082
None 1440 (88.1%) 1521 (89.7%) 1525 (90.3%) 1471 (89.5%) 1411 (91.0%)
Allopurinol 188 (11.5%) 167 (9.8%) 159 (9.4%) 169 (10.3%) 134 (8.6%)
Febuxostat 5 (0.3%) 6 (0.4%) 0 (0.0%) 1 (0.1%) 2 (0.1%)
Benzbromarone 2 (0.1%) 2 (0.1%) 4 (0.2%) 1 (0.1%) 4 (0.3%)
Sulfinpyrazone 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.1%) 0 (0.0%)
Laboratory values at randomization
Haemoglobin (g/L) 137.31±15.20 138.84±15.66 139.86±15.48 140.71±16.42 140.06± 17.09 <0.001
Albumin (g/L) 42.71± 3.08 42.71± 3.09 42.80± 3.14 42.76± 3.16 42.93± 3.29 0.249
Sodium (mmol/L) 141.34± 3.14 141.67± 3.02 141.45± 2.97 141.38± 2.96 141.43± 3.06 0.084
Any ICD (including CRT-D) use 197 (12.0%) 214 (12.6%) 250 (14.8%) 273 (16.6%) 283 (18.2%) <0.001
CRT 90 (5.5%) 104 (6.1%) 117 (6.9%) 120 (7.3%) 132 (8.5%) 0.010
BNP (pg/mL) 231 (147.0–413.3) 241.2 (145.3–420.7) 248.4 (150.9–452.9) 253.7 (157.5–478.4) 310.2 (171.8–631.7) <0.001
NT-proBNP (pg/mL) 1374 (792–2715) 1527.5 (862–2730) 1548.0 (840–3105) 1669.5 (941–3249) 2132.0 (1104–4707) <0.001
KCCQ clinical summary score 81.3 (62.5–92.7) 81.3 (65.0–92.7) 81.3 (64.1–92.2) 79.2 (63.5–91.7) 77.1 (60.2–90.1) <0.001
Data are numbers (proportion), mean ± standard deviation, and median (interquartile range), as appropriate.
BNP, brain natriuretic peptide; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; eGFR, estimated glomerular filtration rate; HF, heart
failure; ICD, implantable cardioverter defibrillator; KCCQ, Kansas City Cardiomyopathy Questionnaire; NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New
York Heart Association; Q, quintile.
Table 2 Risk of various endpoints according to uric acid levels at randomization
No. events Crude rate per 100 PY Unadjusted HR (95% CI) P-value Adjusted HRa (95% CI) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Primary composite
Q1: <5.4mg/dL 320 9.3 (8.3–10.4) 1.00 (reference) 1.00 (reference)
Q2: 5.4–6.2mg/dL 352 9.8 (8.8–10.9) 1.05 (0.91–1.23) 0.49 1.00 (0.85–1.16) 0.97
Q3: 6.3–7.2mg/dL 382 10.8 (9.8–12) 1.17 (1.01–1.35) 0.042 1.03 (0.88–1.20) 0.71
Q4: 7.3–8.5mg/dL 415 12.5 (11.3–13.8) 1.34 (1.16–1.55) <0.001 1.07 (0.92–1.25) 0.37
Q5: ≥8.6mg/dL 518 17.9 (16.4–19.5) 1.91 (1.66–2.19) <0.001 1.28 (1.09–1.50) 0.003
CV death
Q1: <5.4mg/dL 191 5.2 (4.5–6) 1.00 (reference) 1.00 (reference)
Q2: 5.4–6.2mg/dL 229 6.0 (5.3–6.9) 1.15 (0.95–1.4) 0.14 1.11 (0.91–1.35) 0.29
Q3: 6.3–7.2mg/dL 226 6.0 (5.2–6.8) 1.14 (0.94–1.39) 0.18 1.04 (0.85–1.27) 0.70
Q4: 7.3–8.5mg/dL 252 7.0 (6.2–7.9) 1.34 (1.11–1.62) 0.002 1.17 (0.96–1.43) 0.12
Q5: ≥8.6mg/dL 330 10.2 (9.1–11.4) 1.96 (1.64–2.34) <0.001 1.44 (1.17–1.77) 0.001
HF hospitalization
Q1: <5.4mg/dL 167 4.8 (4.2–5.6) 1.00 (reference) 1.00 (reference)
Q2: 5.4–6.2mg/dL 191 5.3 (4.6–6.1) 1.10 (0.89–1.35) 0.38 1.02 (0.83–1.26) 0.84
Q3: 6.3–7.2mg/dL 229 6.5 (5.7–7.4) 1.34 (1.10–1.64) 0.004 1.14 (0.93–1.40) 0.21
Q4: 7.3–8.5mg/dL 252 7.6 (6.7–8.6) 1.56 (1.28–1.90) <0.001 1.17 (0.95–1.44) 0.14
Q5: ≥8.6mg/dL 325 11.2 (10.1–12.5) 2.28 (1.89–2.75) <0.001 1.37 (1.11–1.70) 0.004
All-cause mortality
Q1: <5.4mg/dL 246 6.7 (5.9–7.6) 1.00 (reference) 1.00 (reference)
Q2: 5.4–6.2mg/dL 282 7.4 (6.6–8.4) 1.10 (0.93–1.31) 0.26 1.07 (0.89–1.27) 0.48
Q3: 6.3–7.2mg/dL 283 7.5 (6.7–8.4) 1.11 (0.94–1.32) 0.23 1.02 (0.85–1.21) 0.86
Q4: 7.3–8.5mg/dL 312 8.7 (7.7–9.7) 1.29 (1.09–1.52) 0.003 1.13 (0.95–1.35) 0.18
Q5: ≥8.6mg/dL 395 12.2 (11.1–13.5) 1.82 (1.55–2.14) <0.001 1.36 (1.13–1.64) 0.001
CI, confidence interval; CV, cardiovascular; HF, heart failure; HR, hazard ratio; PY, person years; Q, quintile.
aAdjusted for the following baseline-variables: age, sex, race, region, systolic blood pressure, heart rate, ejection fraction, New York Heart Association class, history of HF
hospitalization, duration of HF, atrial fibrillation, diabetes, body mass index, prior myocardial infarction, prior stroke, estimated glomerular filtration rate, haemoglobin, sodium,
albumin, randomized treatment (sacubitril/valsartan), diuretic dose, and log N-terminal pro-brain natriuretic peptide.
© 2017 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Cumulative probability of the primary endpoint
according to quintile (Q) of uric acid concentration at random-
ization. CV, cardiovascular; HF, heart failure.
Serum uric acid and baseline
characteristics
Patient characteristics according to quintile (Q1–Q5) of SUA are
shown in Table 1. There were many differences between patients
with higher and lower SUA. Patients with higher SUA were slightly
younger and much more likely to be male. North American and
Western European patients were over-represented among those
with higher SUA, as were patients of Asian and Black race. Although
some differences were small, the patients with higher SUA had an
overall profile suggesting more advanced HF. Specifically, duration
of HF was longer, NYHA class and KCCQ were worse and
a history of prior HF hospitalization was more common. LVEF,
systolic blood pressure and eGFR were lower and heart rate and
NT-proBNP were higher. Of interest, most co-morbidities were
not substantially more common in patients with a higher SUA,
except for atrial fibrillation (Q5 vs. Q1, 44.4% vs. 31.0%). Diuretic
treatment was more frequent in patients with higher SUA (Q5 vs.
Q1, 89.9% vs. 71.6%) and diuretic dose was also larger in those
with higher SUA. Mineralocorticoid receptor antagonists were also
used more often in patients with a higher SUA.
Serum uric acid and clinical outcomes
The rates of the clinical outcomes of interest according to base-
line SUA quintile are shown in Table 2 and Figure 1. These are
shown in relation to SUA displayed as a continuous variable in
Figure 2. The primary composite outcome and both its compo-
nents occurred more frequently in patients with higher UA concen-
trations although, after adjustment for other prognostic variables
(including NT-proBNP, diuretic dose and eGFR) the increase in
risk was only clearly seen in those with the highest levels (Q5,
8.6–17.1mg/dL) using Q1 as reference. Spline analysis suggested
a linear increase in risk above a serum concentration of around
7mg/dL (Figure 2). Results were similar when including use of SUA
lowering drugs at baseline in the multivariable model (supplemen-
tary material online, Table S1). ..
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.. Effect of sacubitril/valsartan on outcomes
according to serum uric acid level
The benefit of sacubitril/valsartan over enalapril was consistent
across SUA quintiles for all outcomes of interest (Table 3; supple-
mentary material online, Figure S3).
Effect of sacubitril/valsartan on serum
uric acid level
During the run-in period, SUA decreased when switching from
enalapril to sacubitril/valsartan and remained lower in the
sacubitril/valsartan group than in the enalapril group at 4, 12,
and 24months after randomization (Figures 3–4 and Table 4). At
4months after randomization, SUA was approximately 0.25mg/dL
(95% CI −0.33, −0.18) lower in the sacubitril/valsartan group and
this difference persisted at 12 and 24months.
Use of serum uric acid lowering agents
before and after randomization
Very few patients (approximately 10%) were treated with a UA
lowering agent at baseline and use did not vary according to SUA.
UA lowering agents were initiated among 301 (7.3%) patients
randomized to enalapril, as compared with 244 (6.0%) among those
assigned to sacubitril/valsartan (between group P= 0.015).
Discussion
Although there are a number of reports of an association between
high SUA and poor clinical outcomes in HF, it has not been clear
whether UA is independently predictive when taking account of
renal function and diuretic therapy, both of which increase UA
and are themselves important markers of worse prognosis. More
importantly, no prior report in patients with chronic HF included
adjustment for natriuretic peptides, which are the single most
powerful predictor of outcomes in HF.6 Our study addresses
these gaps in the evidence to date. We found that even after
accounting for these other variables, SUA remained a predictor of
both death and HF hospitalization, although this was only apparent
at concentrations above approximately 7mg/dL and thus was
most apparent in patients in the highest SUA quintile. Notably, we
observed this relationship between SUA and outcomes in patients
extensively treated with beta-blockers and mineralocorticoid
receptor antagonists, in addition to full-dose renin–angiotensin
system blockade (in most prior studies patients had not been
treated with these contemporary therapies). PARADIGM-HF
included patients with less severe HF than in prior reports on
the role of SUA, and PARADIGM-HF was also a much more
geographically representative cohort.10,11
The precise nature of the link between SUA and prognosis in HF
has been uncertain. One possibility is that high SUA is an epiphe-
nomenon and just a marker of reduced excretion due to renal
impairment or higher diuretic dose. However, our data suggest
there may be additional potential mechanisms as SUA remained
a predictor of outcome after correcting for those variables. High
© 2017 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 2 Associations between serum uric acid level at randomization and outcomes. Adjusted for the following baseline variables: age, sex,
race, region, systolic blood pressure, heart rate, ejection fraction, New York Heart Association class, history of heart failure (HF) hospitalization,
duration of HF, atrial fibrillation, diabetes, body mass index, prior myocardial infarction, prior stroke, estimated glomerular filtration rate,
haemoglobin, sodium, albumin, randomized treatment (sacubitril/valsartan), diuretic dose, and log N-terminal pro-brain natriuretic peptide.
The reference is 7.0mg/dL. CV, cardiovascular.
Table 3 Effects of sacubitril/valsartan vs. enalapril on outcomes according to uric acid quintile at randomization
Q1 Q2 Q3 Q4 Q5 P-value for interaction
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Primary composite 0.75 (0.60–0.83) 0.80 (0.65–0.99) 0.73 (0.59–0.89) 0.88 (0.73–1.07) 0.81 (0.61–0.96) 0.70
CV death 0.73 (0.55–0.98) 0.82 (0.63–1.06) 0.74 (0.57–0.97) 0.91 (0.71–1.16) 0.76 (0.61–0.95) 0.72
HF hospitalization 0.74 (0.54–1.00) 0.80 (0.60–1.07) 0.76 (0.59–0.99) 0.82 (0.64–1.05) 0.83 (0.67–1.03) 0.98
All-cause mortality 0.80 (0.62–1.03) 0.83 (0.66–1.05) 0.85 (0.67–1.07) 0.93 (0.75–1.16) 0.78 (0.64–0.95) 0.80
CV, cardiovascular; HF, heart failure; Q, quintile.
SUA could also reflect increased xanthine oxidase activity and this,
in turn, might result in oxidative stress which is thought to play a
detrimental role in HF.1 It has also been suggested that UA itself has
direct effects likely to be harmful in HF.12 For example, UAmay have
pro-inflammatory and proliferative actions and cause endothe-
lial dysfunction.2 Likewise, UA may be damaging in the kidneys.13
While both possibilities are supported by experimental studies
and mechanistic studies in humans, two small randomized clinical ..
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. studies using xanthine oxidase inhibitors (which lowered SUA
levels) have not shown clear clinical benefit in patients with HF.7,8
In the Impact of Oxypurinol in Patients With Symptomatic
Heart Failure (OPT-HF) study including 405 patients with HFrEF,
oxypurinol reduced SUA by ∼2mg/dL at 24weeks without any
clinical benefit overall, although post hoc analyses suggested pos-
sible benefits in patients with SUA> 9.5mg/dL (approximating to
Q5 in the present analysis).7 However, in the Effects of Xanthine
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Figure 3 Effect of study drug on serum uric acid concentra-
tion. *P< 0.001 for sacubitril/valsartan vs. placebo in a repeated
measures mixed model, with baseline score as a covariate, and
treatment, region, time, and treatment by time interaction as fixed
effects. During the first run-in all patients received enalapril but
changed to sacubitril/valsartan during the second run-in, as illus-
trated below the curves.
Oxidase Inhibition in Hyperuricemic Heart Failure Patients
(EXACT-HF) study, which included 253 patients with HFrEF and
SUA≥ 9.5mg/dL, although allopurinol treatment reduced SUA
by ∼4.2mg/dL at 24weeks, it did not improve clinical status,
health-related quality of life or LVEF.8 Because of their limited
size, neither of these studies definitively answers the question of
whether lowering SUA improves clinical outcomes in HF.
In PARADIGM-HF, treatment with sacubitril/valsartan reduced
SUA and did lead to better clinical outcomes. The reduction in SUA
of approximately 0.25mg/dL with sacubitril/valsartan was much
smaller than in the studies mentioned above and the reduction was
not of a magnitude one would expect to have a substantial effect
on clinical outcomes. Whether (and by how much) this reduction ..
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. in SUA contributed to the reduction in morbidity and mortality
observed in PARADIGM-HF is unknown, given the many other
beneficial mechanisms of action of sacubitril/valsartan. However,
the possibility that lowering SUA might indeed be of value in HF
cannot be excluded based on these findings.
The mechanism of the effect of sacubitril/valsartan on SUA is
unknown. While losartan is known to have an uricosuric action,
this is not the case for other ARBs, including valsartan.14,15 Inhi-
bition of neprilysin may have such an effect as MDL 100,240, a
dual neprilysin-ACE inhibitor, increased urinary UA excretion in
a small (n= 12) study in human volunteers.16 We also found a
significantly lower use of UA lowering agents after randomization
in the sacubitril/valsartan compared with the enalapril group,
which may be an additional clinical benefit of angiotensin receptor
neprilysin inhibition.
SUA levels may also reflect oxidative stress and SUA itself may
increase expression of cytokines and chemokines. Unfortunately,
we did not evaluate these pathways in PARADIGM-HF to see
whether the effect of sacubitril/valsartan on SUA was accompanied
by changes in markers of inflammation.
The question remains as to whether SUA is a marker rather than
a mediator of outcomes and our findings of an association between
SUA and outcomes do not necessarily reflect cause and effect.17
Our study has other limitations. Not all patients had SUA
measured at every time point during follow-up. Patients with an
eGFR <30mL/min/1.73m2 at screening, during the run-in period
or at randomization were excluded, as were patients who expe-
rienced a decrease in eGFR >25% (amended to >35%) between
screening and randomization. While measurement of SUA was
pre-planned, not all of these analyses were. Finally, urinary UA was
not measured.
In conclusion, SUA was an independent predictor of worse
outcomes in PARADIGM-HF, even after multivariable adjustment.
Compared with enalapril, sacubitril/valsartan reduced SUA and
improved outcomes irrespective of SUA.
Figure 4 Point prevalence of serum uric acid (SUA) according to randomized treatment *P< 0.001. Grey bars illustrate number of patients
with measurements at each time point.
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Table 4 Change in uric acid levels at different time points from randomization and from screening
Sacubitril/valsartan Enalapril
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
n LSM (SE) n LSM (SE) LSM of difference (95% CI)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Change from randomization (mg/dL) at
2months 2592 0.00 (0.025) 2574 0.23 (0.025)** −0.23 (−0.16, 0.30)**
4months 2846 −0.01 (0.026) 2838 0.25 (0.026)** −0.26 (−0.33, 0.18)**
12months 3529 0.01 (0.025) 3483 0.26 (0.025)** −0.24 (−0.32, 0.17)**
24months 2521 0.01 (0.032) 2428 0.29 (0.032)** −0.28 (−0.37, 0.19)**
Change from screening (mg/dL) at
0months (randomization) 4052 −0.26 (0.021)** 4076 −0.30 (0.021)** 0.04 (−0.01, 0.10)
2months after randomization 2607 −0.27 (0.027)** 2593 −0.05 (0.027)* −0.21 (−0.29, 0.14)**
4months after randomization 2869 −0.26 (0.027)** 2856 −0.03 (0.027) −0.23 (−0.31, 0.16)**
12months after randomization 3572 −0.25 (0.026)** 3521 −0.02 (0.026) −0.23 (−0.30, 0.15)**
24months after randomization 2558 −0.25 (0.032)** 2464 0.01 (0.033) −0.26 (−0.35, 0.17)**
Data are least square means (LSM) with standard errors (SE) based on a repeated measures mixed model—with the baseline score as a covariate, and treatment, time, and
treatment by time interaction as fixed effects.
CI, confidence interval.
*P< 0.05, **P< 0.0001.
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Figure S1. Distribution of serum uric acid concentrations at
randomization.
Figure S2. Distribution of serum uric acid concentrations at
randomization according to sex and region.
Figure S3. Hazard ratio of sacubitril/valsartan compared with
enalapril for the risk of the primary endpoint according to uric
acid level at randomization (green line).
Table S1. Risk of various endpoints according to uric acid levels
(SUA) at randomization in a model including use of SUA lowering
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